Neurocrine resolves dispute over Huntington's treatment

14-11-2023

Marisa Woutersen

Neurocrine resolves dispute over Huntington's treatment

rafapress / Shutterstock

Neuroscience-focused biopharma ends litigation with four companies | Companies can introduce generic alternatives in the future.


Neurocrine, dispute, Huntington, treatment, Ingrezza, Lupin Pharmaceuticals, Zydus Pharmaceuticals, ANDA, FDA, drug, patent, litigation

LSIPR